1 reports of this reaction
6.3% of all ALUMINUM SESQUICHLOROHYDRATE reports
#1 most reported adverse reaction
ADMINISTRATION SITE PAIN is the #1 most commonly reported adverse reaction for ALUMINUM SESQUICHLOROHYDRATE, manufactured by A.P. Deauville, LLC. There are 1 FDA adverse event reports linking ALUMINUM SESQUICHLOROHYDRATE to ADMINISTRATION SITE PAIN. This represents approximately 6.3% of all 16 adverse event reports for this drug.
Patients taking ALUMINUM SESQUICHLOROHYDRATE who experience administration site pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ADMINISTRATION SITE PAIN is moderately reported among ALUMINUM SESQUICHLOROHYDRATE users, representing a notable but not dominant share of adverse events.
In addition to administration site pain, the following adverse reactions have been reported for ALUMINUM SESQUICHLOROHYDRATE:
ADMINISTRATION SITE PAIN has been reported as an adverse event in 1 FDA reports for ALUMINUM SESQUICHLOROHYDRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ADMINISTRATION SITE PAIN accounts for approximately 6.3% of all adverse event reports for ALUMINUM SESQUICHLOROHYDRATE, making it one of the most commonly reported side effect.
If you experience administration site pain while taking ALUMINUM SESQUICHLOROHYDRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.